Press Releases

Nymox Announces Fexapotide Drug Symposium at AUA Annual Meeting San Francisco ‎May 20

May 2, 2018:

Nymox Pharmaceutical Corporation is pleased to announce that there will be a Symposium on the Company’s lead drug Fexapotide held at the Annual Meeting of the American Urological Association on May 20 in San Francisco.


Nymox Announces $16.25 Million Equity Financing With Qualified Long-Term Investors

April 12, 2018:

Nymox Pharmaceutical Corporation is pleased to announce today that the Company has successfully secured $16.25 million in new equity capital with several professional high net worth investors.


New Online Commentary in UroToday on Fexapotide BPH Clinical Trial Results Publication in World Journal of Urology

April 10, 2018:

A new online published commentary about Nymox’s Fexapotide 2018 clinical trial results publication in World Journal of Urology has newly appeared today on UroToday in its “Beyond the Abstract” section, along with the abstract of the World Journal of Urology article.


Symposium and Panel Discussion on Nymox’s Fexapotide To Be Held at American Urological Association Mid-Atlantic Section Annual Meeting on March 3

March 1, 2018:

Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association Mid-Atlantic Section, in Amelia Island FL March 3.


Nymox Announces US NDA for Fexapotide for BPH

February 5, 2018:

Nymox Pharmaceutical Corporation announced today that the Company will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US.


Fexapotide BPH Phase 3 Clinical Trial Results Published in World Journal of Urology

January 30, 2018:

Nymox Pharmaceutical Corporation reports today that the results of Phase 3 clinical studies of Fexapotide Triflutate undertaken from 2009-2016 are now published in World Journal of Urology.


Nymox Reports 5-Year Results From Prospective Randomized Controlled Prostate Cancer Study of Fexapotide Triflutate in 146 U.S. Men

January 22, 2018:

Nymox Pharmaceutical Corporation reported today top-line 5-year results from Nymox’s U.S. Study NX03-0040. Study NX03-0040 was undertaken starting in 2012 at 44 investigational sites across the U.S. comprising a highly representative sample of 146 men with the biopsy confirmed diagnosis of T1c prostate cancer, which is the most common type of low grade localized prostate cancer.


Nymox Fexapotide Symposium and Panel Discussion at American Urological Association South Central Sectional Annual Meeting in Naples FL

November 27, 2017:

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, South Central Section in Naples, November 27.


Nymox Fexapotide Symposium and Panel Discussion at American Urological Association North Central Sectional Annual Meeting in Scottsdale

November 16, 2017:

Nymox Pharmaceutical Corporation is pleased to report on the Symposium which was held on Fexapotide Triflutate studies at the Annual Meeting of the American Urological Association, North Central Section in Scottsdale, November 15


Symposium and Panel Discussion on Nymox’s Fexapotide To Be Held at American Urological Association North Central Section Annual Meeting in Scottsdale AZ November 15

November 10, 2017:

Nymox Pharmaceutical Corporation is pleased to report that a Symposium on Fexapotide Triflutate studies will be held at the Annual Meeting of the American Urological Association North Central Section, in Scottsdale AZ next week.